Essayer OR - Gratuit
Perplexity's bid for Alphabet's Chrome appears mischievous
Mint Chennai
|August 18, 2025
It could be a tactic to pierce Google's defence in its antitrust case
If you're fighting an antitrust lawsuit that might end up breaking your company into pieces, one defence is to argue that those pieces would wither away if separated from the mother ship, thus creating a worse outcome for the consumer. That's what Google has been doing in the face of the US Department of Justice (DoJ) calls for it to sell Chrome, its market-leading web browser, as part of the remedies for its monopolistic behaviours involving its search business.
As the company wrote on its blog in May, the DoJ's proposal to break off Chrome—which billions of people use for free—would break it and result in a "shadow of the current Chrome," according to Chrome leader Parisa Tabriz. She added that the browser would likely become "insecure and obsolete."
This defence was complicated somewhat on 12 August when it emerged that Perplexity, an AI company, had made an "audacious" (Bloomberg), "longshot" (Wall Street Journal) and "mischievous" (my term) bid to take Chrome off Google's hands for $34.5 billion.
Cette histoire est tirée de l'édition August 18, 2025 de Mint Chennai.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Mint Chennai
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
